Y-mAbs Therapeutics, Inc.
DelistedCIK 1722964fmd_0E8DAJC6A7ZN0E0V4PVRDQCYEBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Jun 30, 2025, 35 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 21 | 35 | 65 | 85 | 88 |
| Cost of revenue | – | – | – | – | – | 2 | 7 | 11 | 15 |
| Gross profit | – | – | – | – | – | 33 | 58 | 73 | 73 |
| Research and development | – | 14 | 34 | 63 | 94 | 93 | 92 | 54 | 49 |
| Selling, general and administrative | – | – | – | 20 | 45 | 55 | 61 | 45 | 55 |
| Total operating expenses | – | 19 | 43 | 83 | – | – | – | – | – |
| Operating income | – | (19) | (43) | (83) | (120) | (115) | (95) | (26) | (31) |
| Other non-operating income (expense) | – | 0 | (0) | 2 | 1 | (2) | (1) | – | – |
| Income before taxes | 17 | (19) | (43) | (81) | (119) | (55) | (96) | (21) | (30) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 1 | (0) |
| Net income from continuing operations | – | – | – | (81) | (119) | (55) | (96) | (21) | (30) |
| Net income | – | (19) | (43) | (81) | (119) | (55) | (96) | (21) | (30) |
| Net income to common shareholders | – | – | – | (81) | (119) | (55) | (96) | (21) | (30) |